Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model

Human Molecular Genetics

Volumn 22, Issue 24, 2013, Pages 4929-4937

  Rodino Klapac, Louise R ^a,b,c   Janssen, Paul M L ^a,b   Shontz, Kimberly M ^c   Canan, Benjamin ^a   Montgomery, Chrystal L ^c   Griffin, Danielle ^c   Heller, Kristin ^a,c   Schmelzer, Leah ^a,c   Handy, Chalonda ^a,b,c   Clark, K Reed ^a,b,c   Sahenk, Zarife ^a,c   Mendell, Jerry R ^a,b,c   Kaspar, Brian K ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DYSTROPHIN; FOLLISTATIN;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; ECCENTRIC MUSCLE CONTRACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNCTIONAL ASSESSMENT; GENE EXPRESSION; GENE TRANSFER; HISTOPATHOLOGY; IN VITRO STUDY; INFLAMMATORY INFILTRATE; MOUSE; MUSCLE CELL; MUSCLE CONTRACTION; MUSCLE FUNCTION; MUSCLE STRENGTH; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; WILD TYPE;

ANIMALS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DYSTROPHIN; FOLLISTATIN; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; MICE; MICE, INBRED MDX; MUSCLE CONTRACTION; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 84888173283     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt342     Document Type: Article

References (41)

1. Harper, S.Q., Hauser, M.A., DelloRusso, C., Duan, D., Crawford, R.W., Phelps, S.F., Harper, H.A., Robinson, A.S., Engelhardt, J.F., Brooks, S.V. et al. (2002) Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med., 8, 253-261.
2. Gregorevic, P., Blankinship, M.J., Allen, J.M., Crawford, R.W., Meuse, L., Miller, D.G., Russell, D.W. and Chamberlain, J.S. (2004) Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med., 10, 828-834.
3. Liu, M., Yue, Y., Harper, S.Q., Grange, R.W., Chamberlain, J.S. and Duan, D. (2005) Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Mol. Ther., 11, 245-256.
4. Yoshimura, M., Sakamoto, M., Ikemoto, M., Mochizuki, Y., Yuasa, K., Miyagoe-Suzuki, Y. and Takeda, S. (2004) AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Mol. Ther., 10, 821-828.
5. Rodino-Klapac, L.R., Janssen, P.M., Montgomery, C.L., Coley, B.D., Chicoine, L.G., Clark, K.R. and Mendell, J.R. (2007) A translational approach for limb vascular delivery of the micro-dystrophin gene without highvolumeor high pressure for treatment of Duchenne muscular dystrophy. J. Transl. Med., 5, 45.
6. Gregorevic, P., Allen, J.M., Minami, E., Blankinship, M.J., Haraguchi, M., Meuse, L., Finn, E., Adams, M.E., Froehner, S.C., Murry, C.E. et al. (2006) rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat. Med., 12, 787-789.
7. Martin, P.T., Xu, R., Rodino-Klapac, L.R., Oglesbay, E., Camboni, M., Montgomery, C.L., Shontz, K., Chicoine, L.G., Clark, K.R., Sahenk, Z. et al. (2009) Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice. Am. J. Physiol. Cell. Physiol., 296, C476-C488.
8. Odom, G.L., Gregorevic, P., Allen, J.M. and Chamberlain, J.S. (2011) Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Mol. Ther., 19, 36-45.
9. Shin, J.H., Pan, X., Hakim, C.H., Yang, H.T., Yue, Y., Zhang, K., Terjung, R.L. and Duan, D. (2013) Microdystrophin Ameliorates Muscular Dystrophy in the Canine Model of Duchenne Muscular Dystrophy. Mol. Ther., 4, 750-757.
10. Lai, Y., Thomas, G.D., Yue, Y., Yang, H.T., Li, D., Long, C., Judge, L., Bostick, B., Chamberlain, J.S., Terjung, R.L. et al. (2009) Dystrophins carrying spectrin-like repeats 16 and 17 anchornNOSto the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J. Clin. Invest., 119, 624-635.
11. Wagner, K.R., Hamed, S., Hadley, D.W., Gropman, A.L., Burstein, A.H., Escolar, D.M., Hoffman, E.P. and Fischbeck, K.H. (2001) Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann. Neurol., 49, 706-711.
12. Malik, V., Rodino-Klapac, L.R., Viollet, L. and Mendell, J.R. (2010) Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy. Ther. Adv. Neurol. Disord., 3, 379-389.
13. Malik, V., Rodino-Klapac, L.R., Viollet, L., Wall, C., King, W., Al-Dahhak, R., Lewis, S., Shilling, C.J., Kota, J., Serrano-Munuera, C. et al. (2010) Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann. Neurol., 67, 771-780.
14. Mendell, J.R., Moxley, R.T., Griggs, R.C., Brooke, M.H., Fenichel, G.M., Miller, J.P., King, W., Signore, L., Pandya, S., Florence, J. et al. (1989) Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N. Engl. J. Med., 320, 1592-1597.
15. Carre-Pierrat,M., Lafoux, A., Tanniou, G., Chambonnier, L., Divet, A., Fougerousse, F., Huchet-Cadiou, C. and Segalat, L. (2011) Pre-clinical study of 21 approved drugs in themdxmouse. Neuromuscul. Disord., 21, 313-327.
16. Baltgalvis, K.A., Call, J.A., Nikas, J.B. and Lowe, D.A. (2009) Effects of prednisolone on skeletal muscle contractility in mdx mice. Muscle Nerve, 40, 443-454.
17. Sali, A., Guerron, A.D., Gordish-Dressman, H., Spurney, C.F., Iantorno, M., Hoffman, E.P. and Nagaraju, K. (2012) Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse. PLoS One, 7, e34204.
18. Rodino-Klapac, L.R., Haidet, A.M., Kota, J., Handy, C., Kaspar, B.K. and Mendell, J.R. (2009) Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve, 39, 283-296.
19. McPherron, A.C., Lawler, A.M. and Lee, S.J. (1997) Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature, 387, 83-90.
20. Lee, S.J. (2004) Regulation of muscle mass by myostatin. Annu. Rev. Cell Dev. Biol., 20, 61-86.
21. Haidet, A.M., Rizo, L., Handy, C., Umapathi, P., Eagle, A., Shilling, C., Boue, D., Martin, P.T., Sahenk, Z., Mendell, J.R. et al. (2008) Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc. Natl. Acad. Sci. U. S. A., 105, 4318-4322.
22. Kota, J., Handy, C.R., Haidet, A.M., Montgomery, C.L., Eagle, A., Rodino-Klapac, L.R., Tucker, D., Shilling, C.J., Therlfall, W.R., Walker, C.M. et al. (2009) Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci. Transl. Med., 1, 6ra15.
23. Qiao, C., Li, J., Jiang, J., Zhu, X., Wang, B., Li, J. and Xiao, X. (2008) Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum. Gene Ther., 19, 241-254.
24. Mendias, C.L., Kayupov, E., Bradley, J.R., Brooks, S.V. and Claflin, D.R. (2011) Decreased specific force and power production of muscle fibers from myostatin-deficient mice are associated with a suppression of protein degradation. J. Appl. Physiol., 111, 185-191.
25. Nakatani, M., Takehara, Y., Sugino, H., Matsumoto, M., Hashimoto, O., Hasegawa, Y., Murakami, T., Uezumi, A., Takeda, S., Noji, S. et al. (2008) Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. FASEB. J., 22, 477-487.
26. Winbanks, C.E., Weeks, K.L., Thomson, R.E., Sepulveda, P.V., Beyer, C., Qian, H., Chen, J.L., Allen, J.M., Lancaster, G.I., Febbraio, M.A. et al. (2012) Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3andmTORindependently of myostatin. J. Cell Biol., 197, 997-1008.
27. Abmayr, S., Gregorevic, P., Allen, J.M. and Chamberlain, J.S. (2005) Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery. Mol. Ther., 12, 441-450.
28. Brunelli, S., Sciorati, C., D'Antona, G., Innocenzi, A., Covarello, D., Galvez, B.G., Perrotta, C., Monopoli, A., Sanvito, F., Bottinelli, R. et al. (2007) Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc. Nat.l Acad. Sci. U. S. A., 104, 264-269.
29. Dumonceaux, J., Marie, S., Beley, C., Trollet, C., Vignaud, A., Ferry, A., Butler-Browne, G. and Garcia, L. (2010) Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice. Mol. Ther., 18, 881-887.
30. Kemaladewi, D.U., Hoogaars, W.M., van Heiningen, S.H., Terlouw, S., de Gorter, D.J., den Dunnen, J.T., van Ommen, G.J., Aartsma-Rus, A., ten Dijke, P. and t Hoen, P.A. (2011) Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy. BMC Med. Genomics, 4, 36.
31. Watchko, J., O'Day, T., Wang, B., Zhou, L., Tang, Y., Li, J. and Xiao, X. (2002) Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum. Gene Ther., 13, 1451-1460.
32. Bogdanovich, S., Krag, T.O., Barton, E.R., Morris, L.D., Whittemore, L.A., Ahima, R.S. and Khurana, T.S. (2002) Functional improvement of dystrophic muscle by myostatin blockade. Nature, 420, 418-421.
33. Parsons, S.A., Millay, D.P., Sargent, M.A., McNally, E.M. and Molkentin, J.D. (2006) Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. Am. J. Pathol., 168, 1975-1985.
34. Bartoli, M., Roudaut, C., Martin, S., Fougerousse, F., Suel, L., Poupiot, J., Gicquel, E., Noulet, F., Danos, O. and Richard, I. (2006) Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A. Mol. Ther., 13, 250-259.
35. Amthor, H., Macharia, R., Navarrete, R., Schuelke, M., Brown, S.C., Otto, A., Voit, T., Muntoni, F., Vrbova, G., Partridge, T. et al. (2007) Lack of myostatin results in excessive muscle growth but impaired force generation. Proc. Nat.l Acad. Sci. U. S. A., 104, 1835-1840.
36. Gilson, H., Schakman, O., Kalista, S., Lause, P., Tsuchida, K. and Thissen, J.P. (2009) Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin. Am. J. Physiol. Endocrinol. Metab., 297, E157-E164.
37. Lee, S.J. (2007) Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS One, 2, e789.
38. Li, Z.B., Kollias, H.D. and Wagner, K.R. (2008) Myostatin directly regulates skeletal muscle fibrosis. J. Biol. Chem., 283, 19371-19378.
39. Heller, K.N., Montgomery, C.L., Janssen, P.M., Clark, K.R., Mendell, J.R. and Rodino-Klapac, L.R. (2013) AAV-mediated Overexpression of Human a7 Integrin Leads to Histological and Functional Improvement in Dystrophic Mice. Mol. Ther., 21, 520-525.
40. Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X. and Samulski, R.J. (2002) Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol., 76, 791-801.
41. Clark, K.R., Liu, X., McGrath, J.P. and Johnson, P.R. (1999) Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum. Gene Ther., 10, 1031-1039.